ELVANSE caps 40 mg bte 30 pce

7680630230058 CH-63023 N06BA12 01.10.2.

Reimbursement limitations:

ELVANSE

Enfants et adolescents:
Uniquement pour le traitement de deuxième ligne du trouble déficitaire de l'attention …

ELVANSE caps 40 mg bte 30 pce
ELVANSE caps 40 mg bte 30 pce
ELVANSE caps 40 mg bte 30 pce
1 / 3
google

Details

Product number
6302305
CPT
-
Packaging group
30
Unit
Kapsel(n)
Composition
lisdexamfetamini dimesilas 40 mg corresp. dexamfetaminum 11.9 mg, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, Kapselhülle: gelatina, E 133, E 171, E 172 (nigrum), E 172 (flavum), Drucktinte: lacca, propylenglycolum, kalii hydroxidum, E 172 (nigrum), pro capsula corresp. natrium 0.3336 mg.

Articles (1)

Elvanse 40 mg, Hartkapseln
Kapseln
30
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
10/04/2025
Professional SmPC
Français
10/04/2025
Professional SmPC
Italien
10/04/2025
Patient information leaflet
Allemand
09/09/2024
Patient information leaflet
Français
09/09/2024
Patient information leaflet
Italien
09/09/2024

Detailed composition

Substance Quantity Type Category
(N/A)
40.0 MG Substance Wirkstoff (Principe actif)
(N/A)
11.9 MG Substance WIZUS
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance FIMDK
(N/A)
- Substance FNIDK
(N/A)
- Substance FTODK
(N/A)
- Substance FTODK
(N/A)
- Substance HNIDK
(N/A)
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
(N/A)
- Substance HNIDK
(N/A)
- Substance FTODK
(N/A)
0.3336 MG Substance HBESI

Reimbursement information

Public price
CHF 117.85
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/07/2017

Authorization holder

Takeda Pharma AG

8152 Opfikon

Authorization information

Swissmedic authorization number
63023
Drug name
Elvanse, Hartkapseln
Galenic form
KAHA
ATC Code
N06BA12
Authorization status
Z
Dispensation category
A+
First authorization
27/03/2014
Authorization expiration date
31/12/9999
IT number
01.10.2.
Domain
Human medicine
Field of application
Aufmerksamkeitsdefizit-Hyperaktivitätsstörung (ADHS)

Packaging details

Description (FR)
ELVANSE caps 40 mg bte 30 pce
Description (DE)
ELVANSE Kaps 40 mg Ds 30 Stk
Market launch
16/11/2016
Narcotic (BTM)
A

Other packaging sizes

ELVANSE caps 30 mg bte 30 pce
30 KAP
View
ELVANSE caps 50 mg bte 30 pce
30 KAP
View
ELVANSE caps 70 mg bte 30 pce
30 KAP
View
ELVANSE caps 20 mg bte 30 pce
30 KAP
View
ELVANSE caps 60 mg bte 30 pce
30 KAP
View